CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Mallinckrodt Hospital Products Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Mallinckrodt Hospital Products Inc.
675 McDonnell Blvd.
Phone: (858) 436-1400p:858 436-1400 Hazelwood, MO  63042  United States Fax: (858) 436-1401f:858 436-1401

This company was Merged or Acquired on 3/19/2014.
This company ceased filing statements with the SEC on 4/1/2014.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
Mallinckrodt Hospital Products Inc., also known as Cadence Pharmaceuticals, Inc. (Cadence), is a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing products principally for use in the hospital setting. The Company has rights to one product, OFIRMEV (acetaminophen) injection, an intravenous (IV), formulation of acetaminophen. The Company in-licensed the United States, and Canadian rights to OFIRMEV from Bristol-Myers Squibb Company (BMS), which sells intravenous acetaminophen in Europe and other markets for the treatment of acute pain and fever under the brand name Perfalgan.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/201312/31/2013YesYesYes--

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board Cam L.Garner 64 7/1/2004 5/1/2004
President, Chief Executive Officer, Director Theodore R.Schroeder 58 5/1/2004 5/1/2004
Chief Financial Officer, Senior Vice President, Treasurer, Assistant Secretary William R.LaRue 61 4/1/2007 6/1/2006
8 additional Officers and Directors records available in full report.

Business Names
Business Name
Cadence Pharmaceuticals Inc.
Cadence Pharmaceuticals, Inc.
CADX

General Information
Outstanding Shares: 89,183,960 (As of 2/21/2014)
Shareholders: 25
Stock Exchange: NASD
Federal Tax Id: 412142317
Fax Number: (858) 436-1401
Email Address: info@cadencepharm.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023